Mesalamine
Active ingredient: Mesalamine
In short: Mesalamine delayed-release tablets are indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.
What is Mesalamine used for?
Mesalamine delayed-release tablets are indicated for the:
induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis.
treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.
Mesalamine dosage
Administration Instructions
Evaluate renal function prior to initiation of mesalamine and periodically while on therapy.
Swallow mesalamine delayed-release tablets whole; do not split or crush.
Administer mesalamine delayed-release tablets with food
.
Drink an adequate amount of fluids
.
Adults
The recommended dosage for the induction of remission in adult patients with mildly to moderately active ulcerative colitis is 2.4 g to 4.8 g (two to four 1.2-g tablets) taken once daily.
The recommended dosage for the maintenance of remission is 2.4 g (two 1.2-g tablets) taken once daily.
Pediatric Patients
The recommended dosage for treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg who can swallow whole tablets is shown in Table 1:
Weight of Pediatric Patient | Once Daily Mesalamine Delayed-Release Tablets Dosage
Week 0 to Week 8 | After Week 8
24 kg to 35 kg | 2.4 g (two 1.2-g tablets) | 1.2 g (one 1.2-g tablet)
Greater than 35 kg to 50 kg | 3.6 g (three 1.2-g tablets) | 2.4 g (two 1.2-g tablets)
Greater than 50 kg | 4.8 g (four 1.2-g tablets) | 2.4 g (two 1.2-g tablets)
How to take Mesalamine — instructions & advice from the label
Renal Impairment
Inform patients that mesalamine may decrease their renal function, especially if they have known renal impairment or are taking nephrotoxic drugs, and periodic monitoring of renal function will be performed while they are on therapy. Advise patients to complete all blood tests ordered by their healthcare provider
.
Mesalamine-Induced Acute Intolerance Syndrome and Other Hypersensitivity Reactions
Instruct patients to stop taking mesalamine and report to their healthcare provider if they experience new or worsening symptoms of acute intolerance syndrome (cramping, abdominal pain, bloody diarrhea, fever, headache, and rash) or other symptoms suggestive of mesalamine-induced hypersensitivity
.
Hepatic Failure
Advise patients with known liver disease to contact their healthcare provider if they experience signs or symptoms of worsening liver function
.
Severe Cutaneous Adverse Reactions
Inform patients of the signs and symptoms of severe cutaneous adverse reactions. Instruct patients to stop taking mesalamine delayed-release tablets and report to their healthcare provider at first appearance of a severe cutaneous adverse reaction or other sign of hypersensitivity
. …
Warnings & precautions
Do not take this medicine if: Mesalamine delayed-release tablets are contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or to any of the ingredients of mesalamine delayed-release tablets
[see Warnings and Precautions (
5.3), Adverse Reactions (
6.2), Description (
11)
].
Renal impairment, including minimal change disease, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported in patients given products such as mesalamine delayed-release tablets that contain mesalamine or are converted to mesalamine. In animal studies, the kidney was the principal organ of mesalamine toxicity
.
Evaluate renal function prior to initiation of mesalamine therapy and periodically while on therapy. Evaluate the risks and benefits of using mesalamine in patients with known renal impairment, history of renal disease, or taking concomitant nephrotoxic drugs. Discontinue mesalamine if renal function deteriorates while on therapy
.
Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from an exacerbation of ulcerative colitis. Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute abdominal pain and bloody diarrhea, and sometimes fever, headache, and rash. Monitor patients closely for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with mesalamine delayed-release tablets.
Hypersensitivity reactions have been reported in patients taking sulfasalazine. Some of these patients may have a similar reaction to mesalamine delayed-release tablets or to other compounds that contain or are converted to mesalamine. …
Mesalamine side effects
The following clinically significant adverse reactions are described elsewhere in labeling:
Renal impairment, including renal failure
Mesalamine-induced acute intolerance syndrome
Hypersensitivity reactions
Hepatic failure
Severe cutaneous adverse reactions
Upper gastrointestinal tract obstruction
Photosensitivity
Nephrolithiasis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
Induction
The most common adverse reactions occurring in at least 1% of mesalamine- or placebo-treated adult patients with mildly to moderately active ulcerative colitis in two eight-week, randomized, double-blind, placebo-controlled trials (Study 1 and Study 2)
are listed in Table 2.
*Reported in at least 1% of patients in at least one mesalamine group and greater than placebo
Adverse Reaction | Mesalamine
Delayed-Release Tablets
2.4 g once daily
(n = 177) | Mesalamine
Delayed-Release Tablets
4.8 g once daily
(n = 179) | Placebo
(n = 179)
Headache | 6% | 3% | <1%
Flatulence | 4% | 3% | 3%
Liver Function Test Abnormal | <1% | 2% | 1%
Alopecia | 0 | 1% | 0
Pruritus | <1% | 1% | 1%
Pancreatitis occurred in less than 1% of patients during induction in clinical trials and resulted in discontinuation of therapy with mesalamine in patients experiencing this event. …
Drug interactions
The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs), may increase the risk of nephrotoxicity. Monitor patients taking nephrotoxic drugs for changes in renal function and mesalamine-related adverse reactions
.
The concurrent use of mesalamine with azathioprine or 6-mercaptopurine and/or any other drugs known to cause myelotoxicity may increase the risk for blood disorders, bone marrow failure, and associated complications. If concomitant use of mesalamine and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts.
Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection
. Consider an alternative, selective assay for normetanephrine.
About this medicine
Each mesalamine delayed-release tablet for oral administration contains 1.2 g
5-aminosalicylic acid (5-ASA; mesalamine), an anti-inflammatory agent. Mesalamine also has the chemical name 5-amino-2-hydroxybenzoic acid and its structural formula is:
Molecular formula: C
7H
7NO
3
Molecular weight: 153.14
Mesalamine, USP is a light tan to pink colored, needle-shaped crystals. Color may darken on exposure to air. It is odorless or may have a slight characteristic odor.
The tablet is coated with a pH-dependent polymer film, which breaks down at or above pH 6.8, normally in the terminal ileum where mesalamine then begins to be released from the tablet core
.The tablet core contains mesalamine with hydrophilic excipients and provides for extended release of mesalamine.
Each mesalamine delayed-release tablet, USP intended for oral administration contains 1.2 g of mesalamine. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 170657d1-1f32-f036-e063-6294a90a4ed4. Read the full official label on DailyMed.